Given that selective pharmacological GLUT8 inhibition is feasible, GLUT8 may be a viable target to abate metabolic dysfunction–associated steatohepatitis and other complications of obesity. This evidence concerns the gene SLC2A8 and obesity due to melanocortin 4 receptor deficiency.